Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2010

View Archived Issues

Pharmacological profile supports evaluation of GSK-1427400 in chronic pain

INNOVATE-PCI trial data support entry of antiplatelet agent elinogrel in phase III trial

Intranasal desmopressin ineffective in relieving renal colic pain

Scientists identify susceptibility locus for HBV-related hepatocellular carcinoma

Bayer Schering claims new hepatocyte growth factor receptor inhibitors

Regeneron provides update on trials of aflibercept in metastatic colorectal cancer

New histamine H4 receptor ligand VUF-11488 to be tested in inflammation models

Positive outcome of decentralized procedure for Faes Farma's bilastine in Europe

Abbott discloses new CANP 1 inhibitors

Enanta Pharmaceuticals claims new antibacterial agents

Merck Frosst Canada presents new acyl-CoA desaturase inhibitors

Shire and Acceleron sign exclusive license agreement for ACTR-IIB molecules

Vanderbilt University claims new allosteric acetylcholine M1 receptor agonists

Anchor Therapeutics and Ortho-McNeil-Janssen to codevelop GPCR-targeted drugs

Daiichi Sankyo's laninamivir is approved for influenza treatment in Japan

Mymetics' HIV vaccine to enter preclinical study in primates

Marshall Edwards to acquire Novogen's isoflavone-related intellectual property

SciMeDent completes acquisition of DiabetRX

Bristol-Myers Squibb initiates tender offer to acquire ZymoGenetics

Debiopharm and Aurigene nominate Debio-0617 as development candidate

FDA approves new 500-mg dose of Faslodex

Phase I data presented on VGX-3100 in HPV-linked cervical dysplasia and cancer

RedHill Biopharma completes transactions for drugs in late-stage clinical development

Genmab reports phase II data on ofatumumab in multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...